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Abstract
The concept of focal therapy in oncologic surgery refers to maximizing healthy tissue preservation
while maintaining excellent cancer control outcomes. Herein, we address the recent advantages in
the field of focal therapy for both kidney and prostate cancer, focusing on technological achievements
and future perspectives.
Introduction and context
The concept of focal therapy in oncologic surgery refers
to maximizing healthy tissue preservation while main-
taining excellent cancer control outcomes by targeting
and destroying only the cancer. Preserving healthy non-
malignant prostate tissue while treating known areas of
prostate cancer (PCa) may translate into quality-of-life
benefits such as potency and continence [1]. On the
other hand, nephron-sparing surgery (NSS) in kidney
cancertreatment preserves renal function and reduces the
chance of end-stage renal disease.
NSS is a widely accepted option in the treatment of renal
masses, in which partial nephrectomy represents the
standard of care for localized renal masses. However, the
concept of focal therapy for PCa has been debated and
will remain under development before it can be widely
introduced into routine clinical practice. Herein, we
address recent advances in the field of focal therapy for
both kidney cancer and PCa, focusing on technological
achievements and future perspectives.
Recent advances
Focal therapy of prostate cancer
From the standpoint of the clinician, there are three
questions that need clarification before considering
focal therapy as routine. First, who are the appropriate
candidates for focal therapy? Second, what are the
treatment options and what is their efficacy for targeting
and destroying prostate tissue? Finally, what are the
outcomes and how should patients be followed?
Recent advancements on this topic regard mainly the first
two questions. To be able to focally ablate cancerous
tissue, we need to visualize and map the location and the
extent of the disease. Currently, routine imaging techni-
ques (ultrasound, computed tomography, magnetic
resonance imaging, and radionuclear imaging) are not
reliable enough to define the spatial distribution of PCa
within the prostate gland. Novelimagingapproachesthat
need validation and further investigation in a focal therapy
setting include several techniques. HistoScanning™
(Advanced Medical Diagnostics, Waterloo, Belgium) is
based on mathematical elaboration of raw ultrasono-
graphic data and is used to attempt to define and
characterize PCa within the gland. This technology may
be promising in accurately detecting PCa foci of at least
0.5 mL, but available results are still limited [2,3] and
further study is required. Contrast-enhanced ultrasound
using microbubbles as contrast agents represents yet
another potentially attractive option to visualize and
characterize PCa [4]. Magnetic resonance technology is
undergoingsignificantdevelopmentsaswell,focusingona
focal therapy application [5].
Despite extensive efforts to develop an adequate imaging
technique to visualize and characterize PCa, these
technologies do not represent routine clinical practice,
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selection for focal therapy of PCa has relied largely on
prostate biopsy [6], but routine office-based biopsy
schemes have been shown to be unreliable for identify-
ing appropriate candidates for focal therapy [7,8]. The
trend is to accept three-dimensional, multicore, transper-
ineal mapping biopsy as a selection tool [9] that is able
to localize and define the extent of cancerous tissue while
providing guidance for subsequent targeted ablation.
The downside of such an extensive biopsy technique is
that it requires hospitalization and is performed in the
operating room under anesthesia. A roughly 10%
incidence of urinary retention has been reported with
the transperineal approach [10].
New technological developments for ablation are being
investigated. Cryoablation and high-intensity focused
ultrasound (HIFU) are well-known thermoablative
technologies for focal therapy and have been studied in
the clinical setting [1,11-13]. Recently, new approaches
to tissue ablation have been proposed; these include
laser photothermal therapy, with the recent publication
of a phase I trial [14], and irreversible electroporation
(which works by disrupting cell membranes with the
application of impulses of electric current) using the
NanoKnife™ (AngioDynamics, Queensbury, NY, USA)
technology [15,16]. These approaches are in the early
phases of development, but preliminary data are
intriguing.
The interest in focal therapy by patients, physicians, as
well as industry is growing rapidly and is accompanied
by considerable research efforts both on the basic science
and clinical sides. We are likely to witness even greater
interest in and implementation of focal therapy for PCa
in the future.
Focal therapy of kidney cancer
Due to the widespread use of abdominal imaging and
the subsequent increase in the detection of incidental
renal lesions without significant decline in kidney
cancer mortality over the years [17], it has become
evident that we now have a new clinical entity – the
small renal mass (SRM). Most SRMs are amenable to
NSS, which represents the gold standard for the
treatment of these lesions. Minimally invasive NSS is
technically challenging, thus limiting its diffusion into
urological practice. In recent years, ablative techno-
logies [cryoablation, HIFU, radiofrequency ablation
(RFA), and others] have been introduced as treatment
options for SRMs [18]. Currently, ablative techniques
areconsideredalternativestoconventionalsurgerymass
bytheAmericanUrologicalAssociationforclinicalstage
T1 renal mass [19].
Renal cryoablation and RFA are the most studied ablative
approaches to date. These procedures can be performed
both laparoscopically and percutaneously with good
outcomes and limited complications. A recent meta-
analysis of cryoablation and RFA results has shown good
oncologic efficacy in the short term and suggested that
cryoablation may be slightly superior to RFA in local
tumor control and risk of disease progression [20]. From
other studies, it appears that the percutaneous approach
may be associated with inferior oncologic outcomes
compared with the laparoscopic technique using RFA
and cryoablation [21]. However, another meta-analysis
found the percutaneous approach to be safer compared
with the laparoscopic one in terms of complications
while offering comparable oncologic outcomes [22].
Both of these retrospective meta-analyses of published
series may have inclusion biases that skewed the results
toward one or the other approach and are limited
by their retrospective nature. While there may be no
solid consensus on the superiority of one or the other
techniqueor approach,itseems clearthatthesetechnolo-
gies offer overall good outcomes and are less technically
challenging compared with laparoscopic/robotic partial
nephrectomy. Therefore, ablative techniques may pro-
pagate the diffusion of focal therapy for SRMs and its
advantages to more patients.
New technologies are currently being investigated for the
ablation of renal masses. These include HIFU [23],
irreversible electroporation [24], and microwave abla-
tion [25]. These are in the early stages of investigation,
and few preclinical, and almost no clinical, data are
available. Further studies will demonstrate whether these
technologies have an advantage over the current thermo-
ablative techniques (cryoablation and RFA).
Implications for clinical practice
Focal therapy of kidney cancer is a viable approach to
SMRs and is rapidly gaining popularity due to short- and
mid-term oncologic efficacy and technical ease as more
andmorecentersintroduceablativeapproachesintotheir
armamentarium. Long-term oncologic outcomes are not
yet available and will need to be critically assessed.
The introduction of focal therapy for PCa has a valid,
albeit debatable, rationale [26]; technological advances
allow for its clinical implementation, and research efforts
are conspicuous in this field. These factors instill a belief
that focal therapy for PCa will shortly become a clinical
reality, challenging the paradigm of whole-gland therapy
of PCa. The diffusion of focal therapy evidently needs
well-designed trials that would provide hard scientific
evidence of the advantages and the drawbacks of this
innovative concept.
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